Kidney health may change how body handles cancer drug
NCT ID NCT05469100
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at how the body processes the drug selpercatinib (LOXO-292) in people with different levels of kidney function. Researchers gave a single dose to 37 volunteers—some with healthy kidneys and some with kidney impairment—and measured drug levels in the blood and urine over 9 days. The goal was to see if kidney problems change how much drug stays in the body or how fast it is removed, which could guide future dosing recommendations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Selpercatinib (also known as LOXO-292)
What this could lead to
If successful, this study could help doctors determine the right dose of selpercatinib for patients with kidney problems, making the drug safer and more effective for them.
What could go wrong
This is an early-phase, small study (37 participants) focused on drug levels, not on treating a disease. Results may not apply to all patients or predict real-world outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anaheim Regional Center
Anaheim, California, 92801, United States
-
Clinical Pharmacology of Miami
Miami, Florida, 33014, United States
-
Orange County Research Center
Tustin, California, 92780, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32809, United States
-
Riverside Clinical Research
Edgewater, Florida, 32132, United States
-
Stanford Health Care, Valley Care Program
Pleasanton, California, 94588, United States